FDA Approves Pralsetinib for Treatment of Adults with Metastatic RET Fusion-Positive NSCLC
Kevin M. Wright
Abstract
The US FDA granted accelerated approval to pralsetinib for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer.
Topics & Concepts
MedicineLenalidomideInternal medicineClinical endpointMultiple myelomaDexamethasoneRefractory (planetary science)Data monitoring committeeOncologyPhases of clinical researchSurgeryClinical trialPhysicsAstrobiologyChronic Lymphocytic Leukemia ResearchAdvanced Breast Cancer TherapiesPARP inhibition in cancer therapy